SK chemicals Site Manager- Specialist doctors pay keen attention to Trast, a treatment for arthritis of the knee.
- Specialist doctors in the USA and Europe praise as “wonderful” the beneficial
effect of a treatment for arthritis of the knee.
- By 2009, sales of Trast will be expanded across China
SK chemicals (Vice Chairman and CEO Kim Chang-geun) presented its patch for arthritis of the knee, Trast, at the exhibition for cutting-edge rehabilitation medical equipment which was held during the 4th World Congress of the International Society of Physical and Rehabilitation Medicine, at which numerous authoritative scholars and experts from the field of rehabilitation medicine gathered. Trast received many favorable comments.
The ISPRM, which was held at COEX in Samseong-dong, Seoul, on June 11, attracted 2,500 scholars and experts in rehabilitation medicine from all around the world, including 800 from Korea, making it the world’s largest academic congress in the field of rehabilitation medicine.
Ten domestic companies including SK chemicals participated in the event, which enabled experts from around the world to come together. The exhibition also provided 133 exhibition booths to 65 companies from nine countries.
At the booth designed to promote Trast, patients suffering from osteoarthritis, neuromuscular disease, spinal cord injury, and pain-related management and disability, as well as doctors specializing in knee arthritis, gathered together and exhibited their keen interest by bombarding SK chemicals with questions about the Trast patch.
Most notably, many knee arthritis specialists from the USA and Europe said that since Trast, the world’s first patch for diseases of the knee joint, is unique and is expected to be effective, they want to apply it to patients in their own countries.
Meanwhile, in August 2006, approval to sell Trast was obtained from China’s State Food and Drug Administration under the brand name of Teresite (特樂思特).
SK chemicals will launch the sale of Trast, beginning in Beijing and Tianjin, and will conduct marketing campaigns in Shanghai and Zhejiang Sheng in 2007 and Guangdong Sheng in 2008. In 2009, it will further expand the sale of Trast to Jiang Sheng, Wuhan and Hongqing.
Since it was first released onto the market in 1996, Trast has built up its reputation as Korea’s representative drug for disease of the knee joint, and received widespread acclaim at the 4th ISPRM. It is now ready to enter the global market, raising our expectations.